• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Extending the curve: survival of EGFR-mutated lung cancer patients in the 21 century.

作者信息

Barrón Feliciano, Zatarain-Barrón Zyanya Lucia, Cardona Andrés F, Arrieta Oscar

机构信息

Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), México City, México.

Clinical and Translational Oncology Group, Clínica del Country, Bogotá, Colombia.

出版信息

J Thorac Dis. 2018 Mar;10(3):1265-1268. doi: 10.21037/jtd.2018.03.28.

DOI:10.21037/jtd.2018.03.28
PMID:29708166
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5906342/
Abstract
摘要

相似文献

1
Extending the curve: survival of EGFR-mutated lung cancer patients in the 21 century.拓展生存曲线：21世纪表皮生长因子受体（EGFR）突变型肺癌患者的生存情况
J Thorac Dis. 2018 Mar;10(3):1265-1268. doi: 10.21037/jtd.2018.03.28.
2
[Level of soluble programmed death-1 ligand 1 in peripheral blood of patients with advanced epidermal growth factor receptor mutated lung adenocarcinoma and its clinical implications].[晚期表皮生长因子受体突变型肺腺癌患者外周血中可溶性程序性死亡-1配体1水平及其临床意义]
Zhonghua Yi Xue Za Zhi. 2016 Dec 27;96(48):3870-3874. doi: 10.3760/cma.j.issn.0376-2491.2016.48.004.
3
Clinical outcomes in patients with advanced epidermal growth factor receptor-mutated non-small-cell lung cancer in South Western Sydney Local Health District.悉尼西南部地方卫生区晚期表皮生长因子受体突变型非小细胞肺癌患者的临床结局
Intern Med J. 2017 Dec;47(12):1405-1411. doi: 10.1111/imj.13555.
4
Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.厄洛替尼治疗的 EGFR 外显子 19 突变型非小细胞肺癌患者的异质性耐药机制：持续存在的 FGFR3 突变、局部转化为 EGFR 突变型小细胞肺癌，以及获得性 T790M EGFR 突变。
Lung Cancer. 2017 Nov;113:14-17. doi: 10.1016/j.lungcan.2017.08.024. Epub 2017 Sep 1.
5
The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base.基于 cBioPortal 数据库的分析：晚期非小细胞肺癌中 TP53 的预后价值及其与 EGFR 突变的相关性。
Lung Cancer. 2018 Sep;123:70-75. doi: 10.1016/j.lungcan.2018.07.003. Epub 2018 Jul 4.
6
Brain metastases in patients with non-small cell lung cancer: the role of mutated- with an exon 19 deletion or L858R point mutation in cancer cell dissemination.非小细胞肺癌患者的脑转移：携带外显子19缺失或L858R点突变的突变在癌细胞播散中的作用。
Oncotarget. 2017 Jun 16;8(32):53405-53418. doi: 10.18632/oncotarget.18509. eCollection 2017 Aug 8.
7
Prolonged survival of patients with EGFR-mutated non-small cell lung cancer with solitary brain metastases treated with surgical resection of brain and lung lesions followed by EGFR TKIs.脑和肺部病变手术切除后序贯 EGFR-TKIs 治疗，可使 EGFR 突变型非小细胞肺癌伴孤立性脑转移患者获得长期生存。
World J Surg Oncol. 2017 Oct 16;15(1):184. doi: 10.1186/s12957-017-1252-y.
8
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.雷莫芦单抗联合厄洛替尼治疗未经治疗的表皮生长因子受体突变型、晚期非小细胞肺癌患者（RELAY）：一项随机、双盲、安慰剂对照、III 期临床试验。
Lancet Oncol. 2019 Dec;20(12):1655-1669. doi: 10.1016/S1470-2045(19)30634-5. Epub 2019 Oct 4.
9
Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer.PD-L1 表达和 CD8+T 细胞浸润在 EGFR 突变和 ALK 重排肺癌患者中的临床意义。
Lung Cancer. 2018 Nov;125:86-92. doi: 10.1016/j.lungcan.2018.09.010. Epub 2018 Sep 14.
10
Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer.在III期非小细胞肺癌中，同步放化疗联合厄洛替尼可改善总生存期，但不能改善无进展生存期。
Int J Radiat Oncol Biol Phys. 2015 Jun 1;92(2):317-24. doi: 10.1016/j.ijrobp.2015.02.005.

引用本文的文献

1
Early Incorporation to Palliative Care (EPC) in Patients With Advanced Non-Small Cell Lung Cancer: The PACO Randomized Clinical Trial.早期纳入姑息治疗（EPC）对晚期非小细胞肺癌患者的影响：PACO 随机临床试验。
Oncologist. 2024 Oct 3;29(10):e1373-e1385. doi: 10.1093/oncolo/oyae050.
2
Characterization of reactive intermediates formation in dacomitinib metabolism and bioactivation pathways elucidation by LC-MS/MS: phase I metabolic investigation.通过液相色谱-串联质谱法表征达可替尼代谢过程中反应中间体的形成并阐明生物活化途径：I期代谢研究
RSC Adv. 2018 Nov 19;8(68):38733-38744. doi: 10.1039/c8ra06709k. eCollection 2018 Nov 16.
3
Validated LC-MS/MS assay for quantification of the newly approved tyrosine kinase inhibitor, dacomitinib, and application to investigating its metabolic stability.经验证的 LC-MS/MS 分析测定法，用于定量新型批准的酪氨酸激酶抑制剂达可替尼，并应用于研究其代谢稳定性。
PLoS One. 2019 Apr 4;14(4):e0214598. doi: 10.1371/journal.pone.0214598. eCollection 2019.
4
EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP).表皮生长因子受体扩增和敏感突变与厄洛替尼（MutP-CLICaP）治疗肺腺癌患者的生存相关。
Target Oncol. 2018 Oct;13(5):621-629. doi: 10.1007/s11523-018-0594-x.

本文引用的文献

1
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.奥希替尼治疗未经治疗的 EGFR 突变型晚期非小细胞肺癌。
N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.
2
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.达克替尼对比吉非替尼作为 EGFR 突变阳性非小细胞肺癌患者的一线治疗（ARCHER 1050）：一项随机、开放标签、III 期临床试验。
Lancet Oncol. 2017 Nov;18(11):1454-1466. doi: 10.1016/S1470-2045(17)30608-3. Epub 2017 Sep 25.
3
The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613.苹果试验：AZD9291（奥希替尼）治疗表皮生长因子受体（EGFR）突变的非小细胞肺癌（NSCLC）患者血浆T790M阳性的可行性和活性。欧洲癌症研究与治疗组织（EORTC）1613号试验
Clin Lung Cancer. 2017 Sep;18(5):583-588. doi: 10.1016/j.cllc.2017.02.005. Epub 2017 Mar 1.
4
The safety of afatinib for the treatment of non-small cell lung cancer.阿法替尼治疗非小细胞肺癌的安全性。
Expert Opin Drug Saf. 2016 Nov;15(11):1563-1572. doi: 10.1080/14740338.2016.1236910. Epub 2016 Sep 28.
5
Osimertinib: First Global Approval.奥希替尼：全球首次获批。
Drugs. 2016 Feb;76(2):263-73. doi: 10.1007/s40265-015-0533-4.
6
In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer.体外建模以确定表皮生长因子受体（EGFR）酪氨酸激酶抑制剂对非小细胞肺癌中临床相关EGFR突变体的突变特异性。
Oncotarget. 2015 Nov 17;6(36):38789-803. doi: 10.18632/oncotarget.5887.
7
Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain.表皮生长因子受体（EGFR）突变型肺癌对T790M特异性EGFR抑制剂的获得性耐药：EGFR酪氨酸激酶结构域中第三种突变（C797S）的出现
JAMA Oncol. 2015 Oct;1(7):982-4. doi: 10.1001/jamaoncol.2015.1066.
8
Trends in the Cost and Use of Targeted Cancer Therapies for the Privately Insured Nonelderly: 2001 to 2011.2001年至2011年非老年私人保险人群中靶向癌症治疗的成本和使用趋势
J Clin Oncol. 2015 Jul 1;33(19):2190-6. doi: 10.1200/JCO.2014.58.2320. Epub 2015 May 18.
9
Current and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptors.针对具有异常表皮生长因子受体的非小细胞肺癌的当前及未来靶向治疗方法。
Future Oncol. 2015;11(5):865-78. doi: 10.2217/fon.14.312.
10
Global cancer statistics, 2012.全球癌症统计数据，2012 年。
CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: 10.3322/caac.21262. Epub 2015 Feb 4.